Trial Profile
An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs SG 2000 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Spirogen
- 20 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 20 Jan 2014 New trial record